Biostar Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported loss from operations was $1,528,035 against $6,860,303 a year ago. Loss before income taxes was $1,314,387 against $6,844,223 a year ago. Net loss was $1,314,387 or $0.50 per basic and diluted share against $6,902,448 or $3.12 per basic and diluted share a year ago. For the six months, the company reported loss from operations was $2,567,386 against $7,528,822 a year ago. Loss before income taxes was $2,328,536 against $7,522,789 a year ago. Net loss was $2,328,536 or $0.88 per basic and diluted share against $7,522,789 or $3.40 per basic and diluted share a year ago. Net cash provided by operating activities was $4,856,965 against $353,633 a year ago.